Rocket Pharmaceuticals CFO resigns; appoints interim CFO and new director

ROCKET PHARMACEUTICALS, INC.

Fady Malik appointed to Board effective Mar 10; granted options for 33,199 shares (3-yr vest) and 8,641 shares (1-yr vest).
CFO Carlos Garcia-Parada resigns effective Mar 16 due to personal reasons; will advise through Mar 31.
John Militello, VP Finance and Controller, appointed interim Principal Financial Officer as of Mar 16.
Dr. Malik is EVP R&D at Cytokinetics, cardiologist, clinical professor at UCSF.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Fady Malik

Director

RCKT · ROCKET PHARMACEUTICALS, INC.

Effective: 2022-03-10
Filed: March 11, 2022, 6:59 PM ET

appointed Fady Malik, M.D., Ph.D., to the Board, effective March 10, 2022.

Departed

Carlos Garcia-Parada

Chief Financial Officer and Principal Financial Officer

RCKT · ROCKET PHARMACEUTICALS, INC.

Effective: 2022-03-16
Successor: John Militello
Filed: March 11, 2022, 6:59 PM ET

Carlos Garcia-Parada tendered his resignation as Chief Financial Officer and Principal Financial Officer of the Company, effective March 16, 2022, due to personal reasons.

Appointed (interim)

John Militello

Interim Principal Financial Officer

RCKT · ROCKET PHARMACEUTICALS, INC.

Effective: 2022-03-16
Filed: March 11, 2022, 6:59 PM ET

John Militello, the Company’s Vice President – Finance, Senior Controller, Treasurer and Principal Accounting Officer, was appointed as the interim Principal Financial Officer of the Company, as of the effective date of Mr. Garcia-Parada’s resignation.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Fady Malik was appointed as Director at ROCKET PHARMACEUTICALS, INC..

Action: appointed
Role: Director

Exact text from the filing

appointed Fady Malik, M.D., Ph.D., to the Board, effective March 10, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Carlos Garcia-Parada resigned as Chief Financial Officer and Principal Financial Officer at ROCKET PHARMACEUTICALS, INC..

Action: resigned
Role: Chief Financial Officer and Principal Financial Officer

Exact text from the filing

Carlos Garcia-Parada tendered his resignation as Chief Financial Officer and Principal Financial Officer of the Company, effective March 16, 2022, due to personal reasons.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

John Militello was appointed as Interim Principal Financial Officer at ROCKET PHARMACEUTICALS, INC..

Action: appointed
Role: Interim Principal Financial Officer

Exact text from the filing

John Militello, the Company’s Vice President – Finance, Senior Controller, Treasurer and Principal Accounting Officer, was appointed as the interim Principal Financial Officer of the Company, as of the effective date of Mr. Garcia-Parada’s resignation.

View on SEC.gov

ROCKET PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-22-009118

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.